I can respond to that, Madam Chair.
Our framework is as it is. We do look at risk. We look at risks to intended patients, the ones that the drug is supposed to be used by, and we ensure that it's labelled properly. We have a parallel set of regulatory frameworks that looks at the issue around diversion and abuse. I'll turn in a minute to my colleague to speak a little bit about some of the additional measures that were put in place at the time that OxyContin was approved to hopefully reduce the potential of this product being abused, a deterrent.
Our understanding is that OxyContin as a drug is a very valuable analgesic that's used widely to manage chronic pain. There is a large burden of chronic pain illness nationally, and we've heard from many stakeholders that OxyContin plays an important role in managing those patients' symptoms. So there's a clear efficacy, a clear need, a clear patient population where it makes sense to have this product available. I'm all in support as a federal government of making sure that we can minimize the likelihood that this may be abused, and deter it.